GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Price-to-Operating-Cash-Flow
Switch to:

Biogen (BUE:BIIB) Price-to-Operating-Cash-Flow

: 7.03 (As of Today)
View and export this data going back to 2019. Start your Free Trial

As of today (2023-03-20), Biogen's share price is ARS8131.50. Biogen's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2022 was ARS1,156.39. Hence, Biogen's Price-to-Operating-Cash-Flow Ratio for today is 7.03.

The historical rank and industry rank for Biogen's Price-to-Operating-Cash-Flow or its related term are showing as below:

BUE:BIIB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.05   Med: 14.91   Max: 32.48
Current: 27.72

During the past 13 years, Biogen's highest Price-to-Operating-Cash-Flow Ratio was 32.48. The lowest was 6.05. And the median was 14.91.

BUE:BIIB's Price-to-Operating-Cash-Flow is ranked worse than
69.75% of 648 companies
in the Drug Manufacturers industry
Industry Median: 17.06 vs BUE:BIIB: 27.72

Biogen's Cash Flow from Operations per share for the three months ended in Dec. 2022 was ARS-201.78. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2022 was ARS1,156.39.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Biogen was -61.00% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -36.90% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -13.50% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 8.30% per year.

During the past 13 years, Biogen's highest 3-Year average Operating Cash Flow per Share Growth Rate was 203.40% per year. The lowest was -36.90% per year. And the median was 20.90% per year.


Biogen Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Biogen's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Operating-Cash-Flow
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.98 7.86 9.34 9.86 29.20

Biogen Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Price-to-Operating-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.86 10.34 11.83 16.30 29.20

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Price-to-Operating-Cash-Flow Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Biogen's Price-to-Operating-Cash-Flow falls in comparison to its industry or sector. The grey bar indicates the Price-to-Operating-Cash-Flow's extreme value range as defined by GuruFocus.



Biogen Price-to-Operating-Cash-Flow Calculation

Biogen's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio=Share Price/Cash Flow from Operations per share (TTM)
=8131.50/1156.394
=7.03

Biogen's Share Price of today is ARS8131.50.
Biogen's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS1,156.39.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio=Market Cap/Cash Flow from Operations

Biogen Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Biogen's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines

Other Sources